Extract
Noninvasive ventilation (NIV), continuous positive airway pressure (CPAP) and high-flow nasal cannula (HFNC) can be used as the first line of treatment in coronavirus disease 2019 (COVID-19) patients with respiratory failure, postponing and maybe even avoiding the need for intubation and mechanical ventilation [1]. Recent systematic review and meta-analysis demonstrated that HFNC reduces the need for intubation compared with conventional oxygen, with no change in the death risk or length of stay in the intensive care unit [2, 3]. No direct evidence supports the use of NIV, due to a high failure rate [4]. However, when resources become limited, with no option of invasive ventilation, the use of NIV may be justified. The major caveat of using noninvasive respiratory support in the face of the COVID-19 pandemic is the generation of aerosols, composed of small virus-containing particles, which may remain suspended in the air, with increased risk for healthcare workers [5, 6]. The risk of aerosolisation depends on many variables, including duration of use, flow velocity, mask leakage and patient coughing and cooperation.
Abstract
An innovative constant flow canopy enables noninvasive respiratory support with minimal risk of healthcare worker infection https://bit.ly/3eqgoVZ
Footnotes
Conflict of interest: Y. Adir received personal fees for lecturing and/or consulting from Actelion, Boehringer Ingelheim, Teva, Bayer, GSK, Roche, Novartis, AstraZeneca, Kamada and UT Pharmaceuticals, and research grants from Actelion, Bayer, Boehringer Ingelheim and GSK.
Conflict of interest: O. Segol has nothing to disclose.
Conflict of interest: D. Kompaniets has nothing to disclose.
Conflict of interest: H. Ziso reports that the Israeli innovation authority have granted funds to Tamar Robotics Ltd, such funds along with the funds allocated by our investors were used to develop the system presented in this paper; H. Ziso has a US Provisional Patent Application number 63/001,562, Israel Patent Application number 273616, entitled: “Portable Patient Hood System For Protection Of Medical Staff And Others From Infectious Disease Transmission” pending, and a US Provisional Patent Application number 62/994,614 entitled: “Portable Patient Hood System For Protection Of Medical Staff And Others From Infectious Disease Transmission” pending; and would like to state that: 1) the author is an employee of Tamar Robotics Ltd, that developed the system presented in the paper as a VP of R&D; 2) the author is co-founder of Tamar Robotics Ltd and has holdings in the company (less than 6%); 3) Tamar Niv Breathing Solutions Ltd may sell this product in the future and the author will be receiving dividend or royalties if such sales are made in the future.
Conflict of interest: Y. Yaffe has nothing to disclose.
Conflict of interest: I. Bergman has nothing to disclose.
Conflict of interest: E. Hassidov reports that the Israeli innovation authority have granted funds to Tamar Robotics Ltd, such funds along with funds allocated by our investors were used to develop the system presented in this paper; E. Hassidov has a US Provisional Patent Application number 63/001,562, Israel Patent Application number 273616, entitled: “Portable Patient Hood System For Protection Of Medical Staff And Others From Infectious Disease Transmission” pending, and a US Provisional Patent Application number 62/994,614 entitled: “Portable Patient Hood System For Protection Of Medical Staff And Others From Infectious Disease Transmission” pending; and would like to state that: 1) the author is a part-time employee of Tamar Robotics Ltd that developed the system presented in the paper; 2) the author's brother is Noam Hassidov, CEO of Tamar Robotics Ltd; 3) the author is a fifth year student in the Bar Illan medical school in Israel; 4) the author works once a week in the ER of Carmel Medical Center as an assistant physician; 5) the author has no holdings in Tamar Robotics or any other companies related to the system presented in this paper; 6) Tamar Niv Breathing Solutions Ltd may sell this product in the future.
Conflict of interest: A. Eden has nothing to disclose.
- Received April 4, 2020.
- Accepted April 9, 2020.
- Copyright ©ERS 2020
This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0.